Novartis Says 1 in 4 Breast Cancer Patients Treated With Kisqali Progression-Free Beyond 4 Years
MT Newswires Live
Dec 09
Novartis (NVS) announced trial results Tuesday that showed one in four metastatic breast cancer patients remained progression-free for four or more years following treatment with Kisqali plus endocrine therapy.
The data showed that the patients had a median progression-free survival of 6.8 years, Novartis said.
The results were from a pooled, post-hoc exploratory analysis of first-line patients in the Monaleesa trials, Novartis said.
Shares of the company were up 2% in recent Tuesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.